Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA) on Tuesday announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted applications for TVB-009P, a biosimilar candidate to Prolia (denosumab).
Both applications include all indications approved for Prolia, including conditions with a high risk for fracture such as osteoporosis in postmenopausal women. The FDA and EMA are expected to make decisions in the second half of 2025.
TVB-009P is the first internally developed biosimilar from Teva to be submitted to the FDA. The submissions are supported by a comprehensive data package, including results from Phase 3 clinical trials and pharmacokinetic studies.
Osteoporosis affects millions of women worldwide, increasing their risk of bone fractures. Teva's biosimilar candidate, if approved, could offer a new treatment option for patients with this condition.
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study